FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
FNArena Sector :
Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.39
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS
FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.39
Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$34.16
23 Dec |
-0.020 OPEN $33.31 |
-0.06% HIGH $34.50 |
318,409 LOW $33.31 |
TARGET | |||||
|
OTHER COMPANIES IN THE SAME SECTOR | |||
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY25 Forecast |
FY26 Forecast |
---|---|---|
EPS (cps) | 54.9 | xxx |
DPS (cps) | 43.0 | xxx |
EPS Growth | N/A | xxx |
DPS Growth | N/A | xxx |
PE Ratio | 62.2 | xxx |
Dividend Yield | 1.3% | xxx |
Div Pay Ratio(%) | 78.4% | xxx |
All estimates have been converted into AUD by FNArena at present FX values.
Last ex-div: 05/12 - ex-div 16.59c (franking 0%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | 21.1 |
DPS All | xxx | xxx | xxx | xxx | xxx | 45.3 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 1,629.7 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 276.4 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 398.2 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 7.54 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 7.56 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 7.12 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | 5.92 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | 7.56 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 19.20 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -30.3 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 88 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 85 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 173 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 75 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 8.51 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 314.2 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 19.28 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 647 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 641 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 184 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 49 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
FPH STOCK CHART
FNArena News on FPH
1 |
Rudi’s View: Final Best Buys & Conviction IdeasDec 23 2024 - Rudi's View |
2 |
Rudi’s View: Banks, WiseTech, Redox & Integral DiagnosticsDec 19 2024 - Rudi's View |
3 |
Rudi’s View: Best Buys & Smaller Cap FavouritesDec 12 2024 - Rudi's View |
4 |
FNArena Corporate Results Monitor – 09-12-2024Dec 09 2024 - Australia |
5 |
In Case You Missed It – BC Extra Upgrades & Downgrades – 06-12-24Dec 06 2024 - Weekly Reports |
Latest Medical Equipment & Devices News
1 |
Diagnostic Imaging Radiates OpportunityDec 18 2024 - Small Caps |
2 |
ResMed’s Bounce-Back CompleteOct 29 2024 - Australia |
3 |
Dr Boreham’s Crucible: Pro MedicusSep 04 2024 - Australia |
4 |
Pro Medicus: Don’t Stop Me NowAug 20 2024 - Technicals |
5 |
Dr Boreham’s Crucible: BlinklabMay 20 2024 - Small Caps |
6 |
ResMed Silences The DoubtersApr 29 2024 - Australia |
7 |
Dr Boreham’s Crucible: 4D MedicalApr 23 2024 - Small Caps |
8 |
Uptrend Resumed For ResMedMar 19 2024 - Technicals |
9 |
Dr Boreham’s Crucible: CochlearFeb 28 2024 - Australia |
10 |
Rudi Interviewed: Ongoing Potential In Technology & GrowthFeb 19 2024 - Rudi's View |